Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
Total Valuation
Biogen has a market cap or net worth of $18.10B. The enterprise value is $24.08B.
Market Cap$18.10B
Enterprise Value$24.08B
Share Statistics
Biogen has 146,527,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding146,527,830
Owned by Insiders0.16%
Owned by Institutions0.21%
Financial Efficiency
Biogen’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 18.46%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)18.46%
Return on Capital Employed (ROCE)0.23
Revenue Per Employee1.27M
Profits Per Employee214.62K
Employee Count7,605
Asset Turnover0.34
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Biogen is 13.65. Biogen’s PEG ratio is 0.34.
PE Ratio13.65
PS Ratio0.00
PB Ratio1.33
Price to Fair Value1.33
Price to FCF8.86
Price to Operating Cash Flow7.75
PEG Ratio0.34
Income Statement
In the last 12 months, Biogen had revenue of 9.68B and earned 1.63B in profits. Earnings per share was 11.20.
Revenue9.68B
Gross Profit9.68B
Operating Income5.23B
Pretax Income1.91B
Net Income1.63B
EBITDA0.00
Earnings Per Share (EPS)11.20
Cash Flow
In the last 12 months, operating cash flow was 2.58B and capital expenditures -286.00M, giving a free cash flow of 2.30B billion.
Operating Cash Flow2.58B
Free Cash Flow2.30B
Free Cash Flow per Share15.67
Dividends & Yields
Biogen pays an annual dividend of $22.225, resulting in a dividend yield of ―
Dividend Per Share$22.225
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.55
52-Week Price Change-44.99%
50-Day Moving Average131.65
200-Day Moving Average164.54
Relative Strength Index (RSI)46.53
Average Volume (3m)1.81M
Important Dates
Biogen upcoming earnings date is Jul 23, 2025, TBA Not Confirmed.
Last Earnings DateMay 1, 2025
Next Earnings DateJul 23, 2025
Ex-Dividend DateFeb 02, 2017
Financial Position
Biogen as a current ratio of 1.35, with Debt / Equity ratio of 39.00%
Current Ratio1.35
Quick Ratio0.90
Debt to Market Cap0.28
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Biogen has paid 273.80M in taxes.
Income Tax273.80M
Effective Tax Rate0.14
Enterprise Valuation
Biogen EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 10.55.
EV to Sales2.74
EV to EBITDA0.00
EV to Free Cash Flow10.55
EV to Operating Cash Flow9.23
Balance Sheet
Biogen has $2.60B in cash and marketable securities with $6.62B in debt, giving a net cash position of $4.02B billion.
Cash & Marketable Securities$2.60B
Total Debt$6.62B
Net Cash$4.02B
Net Cash Per Share$27.45
Tangible Book Value Per Share$3.75
Margins
Gross margin is 79.67%, with operating margin of 54.06%, and net profit margin of 16.87%.
Gross Margin79.67%
Operating Margin54.06%
Pretax Margin19.70%
Net Profit Margin16.87%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Biogen is $171.24, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$171.24
Price Target Upside38.62% Upside
Analyst ConsensusModerate Buy
Analyst Count30
Revenue Growth Forecast1.25%
EPS Growth Forecast26.10%